News | August 02, 2021
Glenmark signs agreement with SaNOtize to manufacture NONS
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Turnover of API division of ISLL stood at Rs 856.58 crore
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The group now has 320 approvals and has so far filed over 400 ANDAs
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
